Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Incretin Mimetics
BYETTA
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="Dennis" data-source="post: 58142" data-attributes="member: 1338"><p><strong>Re: Anyone use Byetta?</strong></p><p></p><p>Hi Dave,</p><p></p><p>Funnily enough I did wonder last week what was happening because there has been very little news about the various new developments. It appears that NovoNordisk are expecting to get full approval for Liraglutide in May. This is a once-a-day version of a GLP-1 analogue, similar to exenatide, but their research shows it to be marginally only more effective than Byetta (by 0.3%). The advantage is more in only having one injection a day.</p><p></p><p>Eli Lilly filed in the US for approval of the once a week version (Exenatide LAR) but this was rejected because the FDA weren't happy with the way the trials were reported. They have asked Lilly go re-trial and represent their findings. That will delay the launch until probably September this year. Meanwhile Roche have been pressing ahead with their own once a week version (called taspoglutide) and are confident of gaining approval in July. So looks like Lilly rushed things, screwed up badly and could now get left well behind by the opposition.</p></blockquote><p></p>
[QUOTE="Dennis, post: 58142, member: 1338"] [b]Re: Anyone use Byetta?[/b] Hi Dave, Funnily enough I did wonder last week what was happening because there has been very little news about the various new developments. It appears that NovoNordisk are expecting to get full approval for Liraglutide in May. This is a once-a-day version of a GLP-1 analogue, similar to exenatide, but their research shows it to be marginally only more effective than Byetta (by 0.3%). The advantage is more in only having one injection a day. Eli Lilly filed in the US for approval of the once a week version (Exenatide LAR) but this was rejected because the FDA weren't happy with the way the trials were reported. They have asked Lilly go re-trial and represent their findings. That will delay the launch until probably September this year. Meanwhile Roche have been pressing ahead with their own once a week version (called taspoglutide) and are confident of gaining approval in July. So looks like Lilly rushed things, screwed up badly and could now get left well behind by the opposition. [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Incretin Mimetics
BYETTA
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…